Here are what the editors at HealthDay consider to be the most important developments in Pharmacy for January 2019. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the most likely to affect clinical practice.
FDA Approves First Generic Version of Advair for Asthma, COPD
THURSDAY, Jan. 31, 2019 (HealthDay News) — The first generic form of the Advair Diskus (fluticasone propionate and salmeterol inhalation powder) inhaler has been approved by the U.S. Food and Drug Administration.
Small Increase in HbA1c Seen With Switch to Human Insulin in T2DM
THURSDAY, Jan. 31, 2019 (HealthDay News) — Switching from analogue to human insulin is associated with a small increase in hemoglobin A1c (HbA1c) levels, according to a study published in the Jan. 29 issue of the Journal of the American Medical Association.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Methotrexate Well Tolerated, Effective for Psoriasis in Chinese
THURSDAY, Jan. 31, 2019 (HealthDay News) — Methotrexate is well tolerated and effective for psoriasis in a Chinese population and is more effective for those without psoriatic arthritis, according to a study published online Jan. 30 in JAMA Dermatology.
Abstract/Full Text (subscription or payment may be required)
E-Cigarettes More Effective for Smoking Cessation
THURSDAY, Jan. 31, 2019 (HealthDay News) — Electronic cigarettes are more effective for smoking cessation than nicotine replacement therapy, according to a study published online Jan. 30 in the New England Journal of Medicine.
Abstract/Full Text (subscription or payment may be required)
Editorial 1 (subscription or payment may be required)
Editorial 2 (subscription or payment may be required)
Management of MS in Pregnancy Reviewed in U.K. Guideline
THURSDAY, Jan. 31, 2019 (HealthDay News) — It is important to discuss family planning and pregnancy proactively in women of childbearing age who have multiple sclerosis (MS), according to a review published online Jan. 5 in Practical Neurology.
Oral Antibiotics Noninferior to IV for Bone, Joint Infection
THURSDAY, Jan. 31, 2019 (HealthDay News) — For patients being treated for bone or joint infection, oral antibiotics are noninferior to intravenous antibiotics, according to a study published in the Jan. 31 issue of the New England Journal of Medicine.
Abstract/Full Text (subscription or payment may be required)
Infective Endocarditis Related to Injection Drug Use Rising
WEDNESDAY, Jan. 30, 2019 (HealthDay News) — The risk for infective endocarditis related to injection drug use increased from 2006 to 2015, according to a study published online Jan. 28 in CMAJ, the journal of the Canadian Medical Association.
Expanded Recall Announced for Ibuprofen Oral Suspension Drops
Homicide, Suicide, and Overdose Leading Causes of Maternal Death
Model Predicts Poor Outcomes Within 30 Days of a Before Medically Advised Discharge
Fewer Than Half of Drug Overdose Survivors Go to the Hospital
2000 to 2023 Saw Rise in Pediatric Exposure to Medications, Supplements
Long-Term Medication Adherence Tied to Lower Cardiovascular Event Rate in Type 2 Diabetes
Warning Symptoms, Clinical History Can Predict Sudden Cardiac Arrest
Protocol IDs Patients Who Can Be Treated While Seated in the ED
Once-Weekly Oral Islatravir-Lenacapavir Noninferior to Daily B/F/TAF in HIV